UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 11,918	$ 10,656
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	454	483
Amortization	4,837	4,996
Provision for (recovery of) losses on accounts receivable	21	20
Amortization of Right of Use Assets	39	32
Deferred income taxes	(409)	(160)
Stock-based compensation expense	121	123
Tax benefit attributable to exercise of stock options	0	11
Changes in operating assets and liabilities
Accounts receivable and other receivables	(1,059)	(802)
Inventories	(2,065)	(161)
Prepaid expenses and other current assets	(5)	(35)
Accounts payable	540	242
Accrued expenses	1,075	811
Total adjustments	3,549	5,560
Net cash provided by operating activities	15,467	16,216
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(771)	(299)
Intangible assets	(9)	0
Net cash used in investing activities	(780)	(299)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	43	281
Common stock purchased and retired	(2,495)	0
Payment of dividends	(2,112)	(3,116)
Net cash used in financing activities	(4,564)	(2,835)
Effect of exchange rate changes on cash	(1,586)	(351)
Net increase in cash and cash equivalents	8,537	12,731
Cash at beginning of period	60,974	51,590
Cash at end of period	69,511	64,321
Cash paid during the period for income taxes	3,502	3,094
Cash paid during the period for interest	$ 0	$ 0